NEW YORK – AnPac Bio-Medical Science said on Monday that it has received notice from Nasdaq that it has not met the exchange's minimum bid price requirement of $1.00 per share.
Based on the closing bid price of AnPac Bio's listed securities from Jan. 24 to March 7, the company has failed to meet the minimum listing requirement. The notification, which was received on March 8, is not a notice of imminent delisting and has no immediate effect on the listing of the company's securities on the exchange, the firm said in a statement.
AnPac Bio has a period of six months to regain compliance, which requires the firm's listed securities price to be at least $1.00 per share for at least 10 consecutive business days. If it doesn't meet the requirements by Sept. 5, it may be eligible for additional time to regain compliance or face delisting, AnPac Bio said.
In January, the firm already received a warning from Nasdaq that it was not in compliance with the exchange's minimum market value of publicly held shares, or MVPHS. To remain listed, the company must maintain a minimum MVPHS of $15 million for at least 10 consecutive business days. AnPac Bio also has a separate listing deficiency, as it has not maintained the minimum market value of listed securities of $50 million. It has until July 18 to regain compliance with the minimum MVPHS requirement, and until March 23 to regain compliance with the minimum market value of listed securities requirement.